Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer

Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer

A promising molecular target for aggressive cancers is the urokinase receptor (uPAR). A fully human, recombinant antibody that binds uPAR to form a stable complex that blocks uPA-uPAR interactions (2G10) and is internalized primarily through endocytosis showed efficacy in a mouse xenograft model of...

Full description

Bibliographic Details
Main Authors: Efrat T. Harel, Penelope M. Drake, Robyn M. Barfield, Irene Lui, Shauna Farr-Jones, Laura Van’t Veer, Zev J. Gartner, Evan M. Green, André Luiz Lourenço, Yifan Cheng, Byron C. Hann, David Rabuka, Charles S. Craik
Format: Article
Language:English
Published: MDPI AG 2019-11-01
Series:Antibodies
Subjects:
antibody-drug conjugate (adc)
urokinase receptor (upar)
targeted therapy
triple-negative breast cancer (tnbc)
cleavable linker
non-cleavable linker
site-specific conjugations
monomethyl auristatin e (mmae)
maytansinoid
Online Access:https://www.mdpi.com/2073-4468/8/4/54

Internet

https://www.mdpi.com/2073-4468/8/4/54

Similar Items